key: cord-0823699-2vjy914c authors: Camiolo, Matthew J.; Gauthier, Marc; Kaminski, Naftali; Ray, Anuradha; Wenzel, Sally E. title: Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype date: 2020-06-10 journal: J Allergy Clin Immunol DOI: 10.1016/j.jaci.2020.05.051 sha: f7a6c42e2cd8a5514499907a49556c15ce62e918 doc_id: 823699 cord_uid: 2vjy914c Abstract Background Over 300 million people carry a diagnosis of asthma with data to suggest they are at higher risk for infection or adverse outcomes from SARS-CoV-2. Asthma is remarkably heterogenous and it is currently unclear how patient intrinsic factors may relate to COVID-19. Objective Identify and characterize subsets of asthmatics at increased risk for SARS-CoV-2 infection. Methods Participants from 2 large asthma cohorts were stratified using clinically relevant parameters to identify factors related to ACE2 expression within bronchial epithelium. ACE-2 correlated gene signatures were used to interrogate publicly available databases to identify upstream signaling events and novel therapeutic targets. Results Stratifying by Type 2 inflammatory biomarkers, we identified subjects who demonstrated low peripheral blood eosinophils accompanied by increased expression of the SARS-CoV-2 receptor ACE2 in bronchial epithelium. Genes highly correlated with ACE2 overlapped with Type 1 and 2 interferon signatures, normally induced by viral infections. T cell recruitment and activation within bronchoalveolar lavage cells of ACE2-high subjects was reciprocally increased. These patients demonstrated characteristics corresponding to risk factors for severe COVID-19, including male sex, history of hypertension, low peripheral blood and elevated BAL lymphocytes. Conclusion ACE2 expression is linked to upregulation of viral response genes in a subset of Type-2 low asthmatics with characteristics resembling known risk factors for severe COVID-19. Therapies targeting the interferon family and T cell activating factors may therefore be of benefit in a subset of patients. Clinical Implication Type-2 low asthmatics may be at increased risk for adverse outcome from COVID-19 and deserve increased vigilance upon developing symptoms. Evolving epidemiological data during the COVID-19 pandemic have shed light on 76 populations at risk for severe infection. Chronic lung disease is consistently listed as a 77 risk factor, though relationship to specific underlying conditions is unclear(1). The 78 impact of asthma remains particularly controversial(2), ranging anywhere from 79 protective effect to 3-fold risk for hospitalization in young adults(1). Further, asthma is a 80 remarkably heterogenous disease with differing underlying immunobiology, severity and 81 response to treatment(3). Thus, a more granular understanding of asthma and its 82 subtypes is required to address the controversies related to the health impact of Severe 83 Adult Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). 84 Entry of the SARS-CoV-2 virus is mediated by fusion of the viral spike protein 85 and cellular membranes through interaction with cell surface angiotensin converting 86 enzyme II (ACE2)(4, 5). Previous work confirms ACE2 expression by bronchial 87 epithelial cells (BECs) and supports a link to Type 1 immunity (6, 7). In contrast, 88 asthma, for most, is thought to be a Type-2 (IL-4, 5 and 13) driven immune process. 89 Whether this skewing towards Type-2 immunity and away from Type-1 could alter 90 COVID-19 clinical outcomes is not yet clear. Despite this relationship to Type-2 immunity, the BEC transcriptome of asthma 92 patients, particularly those with severe disease, is markedly heterogeneous and 93 includes both Type-2 and Type-1 signature genes (8-10). This understanding 94 contributed to the current paradigm for defining asthma by the presence or absence of 95 Type-2 biomarkers, such as fraction exhaled nitric oxide (FeNO), blood and sputum 96 eosinophils (5). While Type-2 Hi asthma has been associated with more frequent 97 Camiolo 7 exacerbations, a subset of severe patients exhibit a Type-1 polarized immune response 98 typified by increased 12) . As a known viral response gene, IFN-γ could 99 critically impact COVID-19 disease. Thus, we hypothesized that Type-1 polarization of 100 the immune response in BECs would link to a high risk COVID-19 phenotype which 101 could be identified in relation to ACE2 gene expression. To assess the impact of immune polarization on ACE2 expression, we 103 stratified patients by biomarkers of Type-2 inflammation. We next looked for genes 104 correlated with ACE2 expression to assemble a signature for patients with elevated 105 expression. Ontological term enrichment was performed to ascribe function to these 106 genes and comparison to in vitro stimulation and knockdown condition datasets was 107 done to confirm relationship to pathways and upstream ligands. Patient clustering with 108 our ACE2 gene signature then informed a supervised classification model in which 109 commonly available clinical data is used to predict epithelial gene expression. Patients in the SARP and IMSA cohorts were scored for strength of expression for 151 curated lists of genes related to asthma phenotype. Type-1 (T1) asthma scoring was 152 performed using the geometric mean of using 8 genes identified as upregulated by 153 interferon family members and increased in asthma compared to healthy patients (19) . The Type-2 (T2) score was similarly calculated using 3 genes identified as upregulated 155 by IL-13 stimulation of cells and increased in asthma(10). Hypergeometric overlap of the ACE2 correlated signature was performed via tools 158 available through the NIH Library of Integrated Network-Based Cellular Signatures(20). Comparison with gene lists related to viral infection was accomplished using Enrichr(21) 160 to interrogate the "Virus Perturbations from GEO" dataset. Metadata from gene lists 161 that demonstrated significant overlap with p-value < 0.05 after correction for multiple 162 testing were mined for semantic similarity using hierarchical clustering based on cosine 163 similarity measurement, identifying SARS-CoV as the most common term. CommunityMap was used to interrogate over-expressed gene signatures and ligand 165 stimulation conditions for similarity with ACE2-correlated genes. Using Enrichr, the ACE2-correlated gene signature was used to interrogate the 168 ChEA(22), TTRUST(23) and ENCODE(24) databases for overlapping target sets. Metadata from target lists that demonstrated significant overlap with p-value < 0.05 after 170 correction for multiple testing were mined for semantic similarity using hierarchical 171 clustering based on cosine similarity measurement, allowing for quantification of term 172 frequency for pie chart assembly. Genes identified as transcription factor targets from interrogation of databases as 175 detailed above were used for network assembly using the R package linkcomm (version 1.0-12)(25). Connectivity between network neighborhoods was used to identify 177 transcription factors most likely to account for ACE2-correlated genes via greatest 178 connectedness scoring. Network complexity was set to medium with filtering of gene ontology terms that met a 188 p-value of overlap < 0.001. Redundant term collapse was enabled. The determination of patient group number used to cut the dendrogram of epithelial 191 expression data for both IMSA and SARP cohorts was accomplished via gap statistic 192 calculation using the R package "NbClust" (version 3.0)(29). Following filtering for the cohort specific ACE2-correlated gene signature, dendrograms 195 were assembled using Euclidean distance and the "ward.D2" method of hierarchical clustering. The dendrograms were then cut using the number of patient groups 197 determined by gap statistic as described above. In order to build a predication model for BEC expression cluster using cell count and Ligand response datasets were aggregated for pie chart construction using semantic 219 similarity as described above. A graph-based approach was taken to identify genes that 220 belonged to at least 5 response conditions to form a list of "hub" genes. This list was The GEO accession number for the RNA-seq data from IMSA will be available prior to 235 publication of this manuscript. Software and custom code will be available upon request. Figure E4 ). Implementing a graph-based 271 approach to resolve redundancy between enrichment sets, we identified STAT1 and 272 IRF1 as having the highest predicted activity in relation to expression of ACE2-273 correlated genes ( Figure 1F ). Supporting a role for STAT1 and IRF1 activation, putative 274 binding sites were identified at the ACE2 locus on the human X chromosome using 275 genomic regulatory factor databases(26, 33) (Online Repository Figure E3 ). Importantly, the correlation between ACE2 and viral response genes was independently 277 recapitulated in the SARP cohort (Online Repository Figure E5 ). Transcripts associated 278 with ACE2 overlapped between cohorts and shared enrichment for ontological terms 279 such as regulation of interferon-alpha and -gamma as well as viral release from host 280 cell(34, 35). These gene ontology terms, as well as those relating to T cell activation, Figure 3E ). This model did not require information on asthma severity for 315 classification, making it broadly applicable for BEC gene expression prediction. Examination of model variables showed that readily available parameters could identify 317 ACE2-high patients who are potentially at risk for severe COVID-19 ( Figure 3F ). To further investigate this relationship, we performed TF target analysis on BAL 341 transcription data and found enrichment of E2F family-related genes in association with 342 BEC ACE2 ( Figure 4D ). The transcriptional repressor E2F2 may cooperate with CREB 343 in the silencing of genes responsible for DNA metabolism and cell cycle regulation (48), 344 suggesting that loss of T cell quiescence is associated with higher levels of BEC ACE2. Gene ontology term enrichment confirms this relationship between T cell cytotoxicity 346 and expression of ACE2 in bronchial epithelium ( Figure 4E ). Targeted treatments for Type-2 low asthma have remained elusive despite 349 widespread recognition of this phenotype(49). To identify candidates for intervention 350 that may counteract changes seen in ACE2 high epithelium, we interrogated the LINC 351 database to find ligand stimulation conditions that induce similar patterns in vitro ( Figure 352 Camiolo 19 5A). In aggregate, this list included multiple hits for type I and II interferons, TNFα and 353 IL-1 ( Figure 5C ). As many of these genes were listed in multiple sets, we employed a 354 graph-based approach to identify hub genes shared between them ( Figure 5B ). Querying the database for knockdown conditions shown to decrease expression of 356 these hub genes, we pinpointed cytokines that may be reasonable targets for 357 abrogating ACE2-correlated gene expression ( Figure 5D ). This included T cell Given the known heterogeneity in asthma, it is not surprising that reports on 369 COVID-19 outcomes in relation to the disease have reported conflicting results. We 370 found that a subset of asthma patients display a distinctive gene expression signature in 371 their bronchial epithelium which includes co-expression of ACE2 with a viral response 372 network related to interferon signaling amongst others. These patients exhibit a high 373 Type-1 and low Type-2 epithelial gene expression signature, in addition to low blood 374 eosinophils, consistent with a Type-2 low asthma phenotype. Separately, BAL cells 375 from these individuals show reciprocal increase in their expression of upstream 376 signaling molecules, including CCL3, IL36B and IFNA16 and IL1B, consistent with 377 compartmental crosstalk. These participants were exclusively male and had higher 378 diastolic blood pressure. Consistent with a higher risk phenotype, they also had 379 eosinopenia, lymphopenia, a higher neutrophil to lymphocyte ratio in peripheral blood 380 and increased BAL lymphocytes (2, 36, 38, 51) . TF target analysis of ACE2-correlated 381 genes identifies potential binding sites for STAT1 and IRF1 at the ACE2 genomic locus, 382 with growing evidence to suggest that ACE2 expression is indeed positively regulated 383 by upstream interferon stimulation(7). These data suggest activation of host response 384 pathways in some asthma patients may in fact be deleterious during the COVID-19 385 pandemic. Further work is needed to confirm the ability to mitigate SARS-CoV-2 386 infectivity via decrease of cell surface ACE2 through manipulation of specific signaling 387 pathways. As part of these analyses, another PC was identified (PC4) with shared severity 389 and exacerbation measures but had high blood eosinophils and low ACE2. This cluster is consistent with a recent report that the Type-2 cytokine IL-13 is suppressive of 391 ACE2 expression in BECs(52). This suppression may explain the associated lower 392 nasal epithelial ACE2 expression in children with atopic asthma. Interestingly, low ACE 393 in children was not associated with high blood eosinophils, suggesting differences 394 between children and adults, and perhaps contributing to the largely low risk of children 395 for severe . It is important to note that patients in both the IMSA and SARP cohorts were not Hospitalization Rates 422 and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -423 COVID-NET, 14 States Risk factors for severity and mortality in adult 425 COVID-19 inpatients in Wuhan Cryo-EM structure of the SARS coronavirus spike glycoprotein 429 in complex with its host cell receptor ACE2 A pneumonia outbreak associated with 431 a new coronavirus of probable bat origin ACE2 receptor expression and severe 433 acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Type 2 and 436 interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium American journal of respiratory and critical care medicine Gene expression in 442 relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways American journal of respiratory and critical care medicine T-helper type 2-driven 445 inflammation defines major subphenotypes of asthma. American journal of respiratory and critical care 446 medicine Severe asthma in humans 448 and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias High IFN-γ and low SLPI 451 mark severe asthma in mice and humans International ERS/ATS 453 guidelines on definition, evaluation and treatment of severe asthma. The European respiratory journal 456 Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute STAR: ultrafast universal RNA-459 seq aligner featureCounts: an efficient general purpose program for assigning 461 sequence reads to genomic features Moderated estimation of fold change and dispersion for RNA-seq 463 data with DESeq2 The sva package for removing batch effects 465 and other unwanted variation in high-throughput experiments Camiolo 24 Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma LINCS Data Portal 2.0: next generation access point 470 for perturbation-response signatures Enrichr: interactive and 472 collaborative HTML5 gene list enrichment analysis tool ChEA: transcription factor 474 regulation inferred from integrating genome-wide ChIP-X experiments TRRUST v2: an expanded reference database of 477 human and mouse transcriptional regulatory interactions linkcomm: an R package for the generation, visualization, and analysis 480 of link communities in networks of arbitrary size and type ConTra v3: a tool to identify 482 transcription factor binding sites across species Cytoscape: a software 485 environment for integrated models of biomolecular interaction networks ClueGO: a Cytoscape 488 plug-in to decipher functionally grouped gene ontology and pathway annotation networks NbClust: An R Package for Determining the 491 Relevant Number of Clusters in a Data Set Lê Cao K-A. mixOmics: An R package for 'omics feature selection 493 and multiple data integration The 495 harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes 496 and proteins ORegAnno 3.0: a community-499 driven resource for curated regulatory annotation Gene ontology: tool for 501 the unification of biology. The Gene Ontology Consortium Neutrophil-to-Lymphocyte Ratio Predicts Severe 505 Illness Patients with 2019 Novel Coronavirus in the Early Stage Does comorbidity increase the risk of patients with COVID-19: 507 evidence from meta-analysis Clinical characteristics of 140 patients 509 infected with SARS-CoV-2 in Wuhan Eosinopenia and elevated C-reactive protein 511 facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study Camiolo 25 Epithelial cell-derived cytokines: more than just signaling 514 the alarm Recognition of cluster of 516 differentiation 1 antigens by human CD4−CD8>− cytolyTc T lymphocyte CC Chemokine Ligand 3 (CCL3) Regulates 519 CD8+-T-Cell Effector Function and Migration following Viral Infection IL-6 in inflammation, immunity, and disease Function and Regulation of IL-36 Signaling in Inflammatory 524 Diseases and Cancer Development Interleukin-36 in Infectious and Inflammatory Skin Diseases The inflammasome starts rolling IL-6 as a keystone cytokine in health and disease E2F2 and CREB 531 cooperatively regulate transcriptional activity of cell cycle genes Asthma phenotypes: the evolution from clinical to molecular approaches. Nature 534 medicine The use of anti-inflammatory drugs in the 536 treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical 537 immunologists from China Why tocilizumab could be an effective treatment for severe COVID-19? Asthma and Expression of the SARS-CoV-2 Receptor, ACE2. The Journal of allergy 542 and clinical immunology COVID-19 patients' clinical 544 characteristics, discharge rate, and fatality rate of meta-analysis